Pamela Esposito, Director at Kymera Therapeutics, Inc. (KYMR), sold 54,126 shares at $82.34 ($4.4M) on 2025-12-17, disclosed to the SEC on 2025-12-17.
Scheduled sale ($4.4M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $81.56 | 14,505 | $1.2M | 26.6% |
| 2 | $81.56 | 14,505 | $1.2M | 26.6% |
| 3 | $82.34 | 7,959 | $655K | 14.7% |
| 4 | $82.34 | 7,959 | $655K | 14.7% |
| 5 | $83.45 | 4,099 | $342K | 7.7% |
| 6 | $83.45 | 4,099 |
| $342K |
| 7.7% |
| 7 | $84.07 | 1,000 | $84K | 1.9% |
| Total | $82.12 avg | 54,126 | $4.4M | 100% |
| Filing → |
| KYMR | SELL | 2026-01-20 | $707K | — | Filing → |
| KYMR | SELL | 2025-06-03 | $245K | — | Filing → |
| KYMR | SELL | 2024-12-02 | $123K | — | Filing → |